News

EIC Accelerator - selected companies June 2023 cut-off

Published on
| 3 years ago
Programmes
  • EIC

A new set of 47 companies have been selected to receive European Innovation Council (EIC) funding, combining grants and equity, following the third 2023 EIC Accelerator cut-off in June 2023. Among these, 4 companies based in Flanders were selected:

Find out more on the Enterpise Europe Netwerk Flanders' website or on the EIC news article.

Enterprise Europe Network Flanders and NCP Flanders, in a joint effort, provide support to companies in the process of applying to the EIC Accelerator. Interested to apply? Contact NCP/EEN Flanders Advisor Magali Parent (magali.parent@vlaio.be).

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2071 articles available Browse all news
  • Defence
  • NATO-EDA

NATO Engine pilot opens second RFI

The NATO Support and Procurement Agency has launched a second request for information for the NATO Engine pilot. The call targets start-ups, SMEs and scale-ups looking for production capacity for defence or dual-use projects. Registration opened on 17 November 2026 and closes on 31 December 2026.

Read more
  • AI Continent
  • European Digital Innovation Hubs

Call for European AI providers opens

The European Commission’s AI Office has launched a call for expression of interest for European AI providers with mature solutions for SMEs. Selected solutions are due to be listed as “EDIH Ready” in a catalogue on the AI-on-Demand Platform and shared with the European Digital Innovation Hubs network. Expressions of interest must be submitted by 17 December 2026 at 17.00 CET, although the call may close earlier after 100 suitable submissions.

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.